论文部分内容阅读
目的 :探讨灭滴灵治疗细菌性阴道病对不良妊娠结局是否有改善作用。方法 :在产科门诊对用阴道分泌物涂片革兰氏染色Nugent诊断标准孕 2 8 32周妇女进行细菌性阴道病筛查 ,对检出的患者随机分为二组 :观察组 5 2例 ,未给予治疗 ;治疗组 5 0例 ,采用灭滴灵阴道用药治疗 (40 0mg ,每天一次 ,7天为一疗程 ) ,必要时再次治疗。并对其妊娠结局进行随访。结果 ;治疗组胎膜早破、未足月胎膜早破及低体重儿的发生率 (分别为 18% ,2 %和 8% )均低于观察组 (分别为 38 5 % ,15 4%和 19 2 % ) ,P均 <0 .0 5。治疗组新生儿平均出生体重 (32 15± 475g)高于观察组 (2 96 5± 6 6 5 g) ,P <0 .0 0 5。治疗组早产、产褥感染和新生儿感染的发生率均低于观察组 ,但无统计学意义 (P >0 .0 5 )。结论 :妊娠晚期灭滴灵阴道用药治疗细菌性阴道病可降低胎膜早破、低出生体重儿的发生率 ,我们认为 ,为了提高产科质量 ,有必要对妊娠妇女进行BV的系统筛查和治疗。
Objective: To investigate whether metronidazole treatment of bacterial vaginosis on adverse pregnancy outcomes have improved effect. Methods: Bacterial vaginosis screening was performed in obstetric clinic for women with vaginal smear Gram stain Nugent diagnostic criteria for 2832 weeks. The patients were randomly divided into two groups: observation group (n = 52) No treatment was given. The treatment group was 50 cases treated with metronidazole vaginal medication (40 mg, once daily, 7 days for one course of treatment), and if necessary, re-treated. And follow-up of their pregnancy outcomes. Results: The incidences of premature rupture of membranes, premature rupture of membranes and low birth weight infants in the treatment group were 18%, 2% and 8% lower than those in the observation group (38.5% and 154% And 19 2%), P <0.05. The mean neonatal birth weight (32 15 ± 475 g) in the treatment group was significantly higher than that in the observation group (2 96 5 ± 6 6 5 g), P <0.05. The incidence of preterm delivery, puerperal infection and neonatal infection in the treatment group were lower than those in the observation group, but not statistically significant (P> 0.05). CONCLUSIONS: Intragestant vaginas in the third trimester of pregnancy may reduce the incidence of premature rupture of membranes and low birth weight infants, and we believe it is necessary to systematically screen and treat BV in pregnant women in order to improve obstetric quality .